Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 2 TO FORM S-1 - INTERCEPT PHARMACEUTICALS, INC. | v324519_s1a.htm |
| EX-23.2 - EXHIBIT 23.2 - INTERCEPT PHARMACEUTICALS, INC. | v324519_ex23-2.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Intercept Pharmaceuticals, Inc.:
We consent to the use of our report dated June 20, 2012, except as to Note 1 which is as of September 26, 2012, with respect to the consolidated balance sheets of Intercept Pharmaceuticals, Inc. and subsidiary (a development stage enterprise) as of December 31, 2010 and 2011, and the related consolidated statements of operations and comprehensive loss, changes in stockholders' equity, and cash flows for each of the years ended December 31, 2010 and 2011 and the information included in the cumulative from inception presentation for the period September 4, 2002 (inception) to December 31, 2011 and to the references to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
New York, New York
September 26, 2012